Spanish Pharma Stock News

Adriano Care SOCIMI (BME:YADR) has just posted its FY 2025 numbers with second half 2024 revenue at €8.676 million and basic EPS of €0.44, while trailing 12 month revenue sits at €17.406 million and basic EPS at €0.89. Over the past few reporting periods the company has seen revenue move from €8.405 million and a basic EPS loss of €0.10 in the second half of 2023 to €8.73 million and basic EPS of €0.45 in the first half of 2024, before landing at the latest figures. This progression has...

Why Amadeus IT Group Is Back on Investors’ Radar Amadeus IT Group (BME:AMS) has drawn fresh attention after a period of mixed share performance, with recent moves in the price inviting closer scrutiny of its valuation and business fundamentals. See our latest analysis for Amadeus IT Group. The latest 1-day share price return of 2.14% decline and 7-day share price return of 4.94% decline fit into a weaker pattern, with year-to-date share price return of 20.52% decline and 1-year total...

Grifols (BME:GRF) reported proof of concept data from its Chronos-PD program. The company found molecular changes linked to Parkinson’s disease in blood plasma. These changes were detected up to 12 years before clinical diagnosis. Grifols, best known for its plasma derived therapies and diagnostic products, is extending that expertise into neurology with Chronos-PD. The early Parkinson’s signal in plasma connects directly to the company’s existing strengths in blood based testing, an area...

Wondering whether Repsol's current share price truly reflects its underlying worth, or if the market is missing something that you should not. Repsol shares last closed at €21.23, with returns of 3.5% over 7 days, a 6.4% decline over 30 days, 29.4% year to date, 114.8% over 1 year, 81.8% over 3 years and 164.5% over 5 years. Recent coverage has focused on Repsol's position as a major integrated energy player and how investor attention on the sector has shifted in light of energy pricing and...

Enagás (BME:ENG) opened 2026 with Q1 revenue of €227.4 million and net income of €56.9 million, equal to basic EPS of €0.22, setting a measured tone for investors watching how the story evolves after a volatile few years. The company has seen quarterly revenue move from €203.4 million in Q1 2025 to €227.4 million in Q1 2026, while trailing twelve month revenue sits at €977.7 million and trailing EPS at €1.27, giving you a clearer read on how top and bottom line have settled recently. Overall,...

As European markets show resilience with the STOXX Europe 600 Index rising by 1.91% amid positive corporate earnings and geopolitical de-escalation, investors are increasingly looking towards small-cap stocks for potential opportunities. In this environment, identifying promising companies like Cox ABG Group and other lesser-known European small caps involves evaluating their growth potential, financial health, and ability to adapt to changing economic conditions.

While Fomento de Construcciones y Contratas, S.A. ( BME:FCC ) might not have the largest market cap around , it saw...

Iberdrola recently reported on its latest shareholder and analyst call that installed power production capacity reached 58,877 MW by the end of the first quarter, a 3.8% year-on-year increase driven by expansions in the United States, Spain, Australia and other European markets. The company also highlighted very large growth in battery energy storage to 683 MW, underlining how fast storage is becoming a more central part of its renewable asset base. Next, we will examine how this rapid...

Grifols (BME:GRF) has been in focus after Health Canada imposed new regulatory conditions on its paid plasma collection centers, and the company moved to refinance and repurchase parts of its debt stack. See our latest analysis for Grifols. Those refinancing steps and the Health Canada conditions arrive after a mixed run for investors, with the latest €9.646 share price sitting alongside a 30 day share price return of 10.14%, a year to date share price return of 13.84%, and a 1 year total...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Aena S.M.E...

Almirall (BME:ALM) is in focus after expanding its collaboration with the Barcelona Supercomputing Center, a move aimed at applying supercomputing, High Performance Computing and Artificial Intelligence to medical dermatology research. See our latest analysis for Almirall. The expanded BSC collaboration lands at a time when Almirall’s share price has gained 11.91% over the past month, while the year to date share price return is slightly negative and the 1 year total shareholder return stands...

If you are wondering whether Banco Santander is starting to look expensive or still offers value after its strong run, this article breaks down what the current share price might be implying. The stock last closed at €11.04, with returns of 5.0% over 7 days, 14.1% over 30 days, 7.7% year to date, 90.4% over 1 year and 241.4% over 3 years, so recent performance is front of mind for many investors thinking about risk and reward. Recent coverage has focused on Banco Santander as a major...

Why CaixaBank Stock Is on Investor Radars Today CaixaBank (BME:CABK) has drawn fresh attention after recent share price moves, with the stock showing positive returns over the past week, month and past 3 months, prompting closer scrutiny of its current valuation. See our latest analysis for CaixaBank. At a share price of €10.855, CaixaBank has paired a 30 day share price return of 5.70% with a very strong 1 year total shareholder return of 74.29%, suggesting recent momentum is building on an...

Endesa (BME:ELE) has entered into a tailor made financial agreement with Sonnedix to hedge Sonnedix's long term positions. The deal focuses on providing a customized hedge solution for a renewable energy producer operating in Spain's energy market. For investors tracking Endesa at a share price of €36.82, this move highlights how the company is using financial products to deepen its role with renewable energy clients. The stock has recorded a 50.6% return over the past year and a 116.6%...

BBVA Corporate & Investment Banking, part of Banco Bilbao Vizcaya Argentaria (BME:BBVA), has entered a vendor financing partnership with Envision Energy. The agreement is designed to support Envision Energy's international clean technology projects across Europe, Asia, and Latin America. The arrangement focuses on providing flexible financing structures tailored to large scale clean energy deployments. For investors watching BME:BBVA, this new vendor financing deal sits at the intersection...

Iberdrola overview and recent performance snapshot Iberdrola (BME:IBE) has been on many investors’ radars after a solid year for the shares, with a 1 year total return of 33.6% and year to date return of 6.8%. Over the past month the stock has been broadly flat, with a 0.8% return, while the past 3 months show an 8.7% gain, giving a sense of how recent momentum compares with the longer trend. See our latest analysis for Iberdrola. For Iberdrola, the recent softness in the 1 week share price...

The European stock market has recently experienced a notable upswing, with the pan-European STOXX Europe 600 Index rising by 3.05% amid improved investor sentiment following geopolitical developments. Despite this positive momentum, economic uncertainties persist, such as potential stagflationary pressures and revised growth forecasts by the EU. In this environment, identifying stocks that may be undervalued can present opportunities for investors seeking to capitalize on market...

As European markets rally amid easing geopolitical tensions, investors are increasingly looking towards dividend stocks as a stable source of income in an uncertain economic environment. In light of recent market movements, a good dividend stock is often characterized by consistent payouts and the ability to weather economic fluctuations, making them an attractive option for those seeking reliable returns.

In early April 2026, Banco Santander, S.A. completed several US dollar bond issues, including US$400 million of floating‑rate notes due 2029 and US$3.25 billion of fixed‑rate senior and non‑preferred notes maturing between 2029 and 2036, all issued at around par and featuring callable, unsecured, unsubordinated structures. Over roughly the same period, the bank disclosed that it has invested about €2.7 billion in an ongoing share buyback programme, retiring around 16.8% of its 2021 share...

Capital reduction and what it means for Endesa shareholders Endesa (BME:ELE) has moved ahead with a capital reduction, cancelling 17 million treasury shares under its Share Buyback Programme and adjusting total share capital to about €1.25b. This cancellation reduces the number of shares in circulation to just over 1b. This change can influence metrics such as earnings per share and ownership concentration once the capital reduction is formally registered. See our latest analysis for...

Wondering if Telefónica at €3.90 is offering genuine value or just looks cheap on the surface? This article walks through the key clues in the current share price so you can judge that for yourself. The stock has returned 2.5% over the past week, 8.8% over 30 days, 12.0% year to date and 6.5% over the last year, with longer term returns of 15.1% over 3 years and 42.6% over 5 years. Recent coverage of Telefónica has focused on its position in European telecoms, its capital allocation choices...

Repsol reported past Q2 2025 adjusted income of €702 million, an 8% quarter-over-quarter increase, with operating cash flow rising 50% to €1.70 billion despite a €175 million EBIT impact from Iberian power outages. The company also reaffirmed its full-year guidance for €6.00 billion in operating cash flow, signalling management’s confidence in cash generation even after recent disruptions. We’ll now examine how this reaffirmed €6.00 billion operating cash flow guidance could influence...

It looks like Banco Bilbao Vizcaya Argentaria, S.A. ( BME:BBVA ) is about to go ex-dividend in the next three days. The...

Almirall, S.A. recently reported positive long-term interim Phase 3b ADlong results for lebrikizumab in moderate-to-severe atopic dermatitis, showing sustained efficacy and a consistent safety profile over up to four years, at the American Academy of Dermatology meeting in Denver. The data, including high rates of near-complete skin clearance and itch relief mostly achieved without topical corticosteroids, underline lebrikizumab’s potential to anchor Almirall’s European dermatology franchise...